论文信息 - Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy - 字舞流文

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy

P. Nowak | O. Blennow | R. Folkman | Tuulikki Tovatt | Karin Pettersson

[1] M. Landray,et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[2] M. Naqvi,et al. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19) , 2021, Obstetrics and gynecology.

[3] A. Odibo,et al. Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report , 2021, American Journal of Obstetrics and Gynecology.

[4] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[5] Jasmine Rah,et al. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State , 2021, American Journal of Obstetrics and Gynecology.